Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $116.2 million.

  • Xeris Biopharma Holdings' Total Current Liabilities rose 2767.41% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 2767.41%. This contributed to the annual value of $100.4 million for FY2024, which is 551.51% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Total Current Liabilities is $116.2 million, which was up 2767.41% from $95.2 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Total Current Liabilities ranged from a high of $116.2 million in Q3 2025 and a low of $37.3 million during Q3 2021
  • Over the past 5 years, Xeris Biopharma Holdings' median Total Current Liabilities value was $79.7 million (recorded in 2023), while the average stood at $81.1 million.
  • In the last 5 years, Xeris Biopharma Holdings' Total Current Liabilities skyrocketed by 18021.41% in 2021 and then plummeted by 1024.16% in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Total Current Liabilities stood at $79.0 million in 2021, then dropped by 6.86% to $73.6 million in 2022, then increased by 29.3% to $95.2 million in 2023, then grew by 5.52% to $100.4 million in 2024, then grew by 15.69% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $95.2 million for Q2 2025, and $95.1 million during Q1 2025.